GPT Healthcare Ltd (GPTHEALTH)
🎯 Key Takeaways
- GPT Healthcare is in a strategic expansion and operational consolidation phase, transitioning from early-stage growth to scalable maturity in tertiary care across Eastern India. Management is actively investing in capacity expansion while targeting margin improvement and breakeven timelines for new hospitals, supported by strong occupancy trends in mature facilities and specialty-driven revenue growth.
- Revenue declined 0.1% QoQ to ₹126 in Q1FY27.
- ⚠️ Execution risk in new hospital breakeven timelines — management targets 12–24 month payback, but occupancy volatility in emerging markets like Agartal
- Market Cap
- ₹1,280
- P/E Ratio
- 27.1
- P/B Ratio
- 8.09
- ROE
- 29.9%
- ROCE
- 27.4%
- Debt/Equity
- 0.60
- Promoter
- 65.6%
📖 The Story
GPT Healthcare is in a strategic expansion and operational consolidation phase, transitioning from early-stage growth to scalable maturity in tertiary care across Eastern India. Management is actively investing in capacity expansion while targeting margin improvement and breakeven timelines for new hospitals, supported by strong occupancy trends in mature facilities and specialty-driven revenue growth.
📰 What's Happening
In Q1 FY27, GPT Healthcare reported 18.2% YoY revenue growth and 66% YoY PAT growth, with EBITDA margin expanding to 20.4% and PAT margin at 9.9%, driven by robust occupancy and specialty mix. The company advanced its Jamshedpur hospital commissioning toward Q4 FY27 completion and plans to exceed 1,000 beds within two years. Capex for the 150-bed Jamshedpur expansion is nearly complete at INR70 lakhs per bed. Management highlighted recovery in Agartala (51% occupancy) and stable performance in mature hospitals, while targeting 15% revenue growth in FY27-FY28 with ARPOB growth of 8%. The 37th AGM confirmed a final dividend of ₹1.50 per share (15%) payable in September 2026, with re-appointments of independent directors and ratification of auditor fees.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 119 | 120 | 126 | 126 |
| Operating Profit | 16 | 14 | 16 | 17 |
| OPM % | 13.4% | 11.3% | 13.0% | 13.7% |
| Net Profit | 11 | 9 | 15 | 13 |
| EPS | ₹1.29 | ₹1.14 | ₹1.78 | ₹1.55 |
Quarterly revenue has remained relatively stable around ₹120–126 crores over the last four quarters, with operating margins gradually improving from 11.3% in Dec 2025 to 13.7% in Jun 2026, indicating operational efficiency gains. Net profit and EPS show sequential improvement, rising from ₹9 crore (EPS ₹1.14) in Dec 2025 to ₹13 crore (EPS ₹1.55) in Jun 2026, reflecting better cost control and margin expansion. This trend aligns with management’s focus on optimizing occupancy and specialty mix, particularly in mature hospitals, while new facilities contribute to growth despite near-term losses.
🔮 Management Outlook & What's Next
Management expressed confidence in sustained growth, targeting 15% revenue expansion in FY27-FY28 and 8% ARPOB growth, underpinned by tertiary care specialization and digital health initiatives. They emphasized asset-light expansion in Tier 1 and Tier 2 cities, with new hospitals expected to breakeven within 12–24 months. The Jamshedpur hospital is on track for commissioning by Q4 FY27, and capacity is planned to exceed 1,000 beds within two years. Management also highlighted cautious exploration of strategic M&A to accelerate footprint, while maintaining focus on clinical excellence and operational scalability.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2022 |
|---|---|
| Equity Capital | 80 |
| Reserves | 78 |
| Borrowings | 96 |
| Total Liabilities | 323 |
| Fixed Assets | 220 |
| Investments | 10 |
| Total Assets | 323 |
The balance sheet indicates a conservative capital structure with total assets of ₹323 crores and borrowings of ₹96 crores as of March 2022, supported by strong equity of ₹80 crores and reserves of ₹78 crores. This suggests disciplined leverage management, with room for strategic investment in expansion without overleveraging. The company appears to be funding growth through a mix of retained earnings and controlled debt, consistent with its asset-light expansion strategy and focus on operational cash flow generation.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2022 |
|---|---|
| Operating | +66 |
| Investing | -5 |
| Financing | -57 |
| Net Cash Flow | +3 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 65.6% | 65.6% | 65.6% | 65.6% |
| FII | 3.2% | 2.7% | 2.8% | 3.0% |
| DII | 6.5% | 6.2% | 6.8% | 6.9% |
| Public | 18.9% | 19.1% | 18.3% | 18.0% |
| # Shareholders | 67,617 | 66,626 | 64,075 | 62,454 |
Institutional investor interest has shown a slight upward trend, with FII holdings increasing from 2.74% in Q3FY26 to 3.03% in Q1FY27, while DII holdings rose from 6.2% to 6.94% over the same period. Promoter holding remains stable at 65.57%. The growing number of shareholders (62,454 in Q1FY27) and increasing public participation suggest rising retail interest. No signs of promoter pledging or significant dilution, indicating confidence in long-term fundamentals.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 61.0 | 22.1% | — | 0.60 |
| MAXHEALTH | 97,412 | 66.8 | 14.4% | — | 0.27 |
| MANIPALHOS | 94,970 | — | — | — | 1.25 |
| ASTERDM | 65,184 | 121.0 | 12.9% | — | 0.17 |
| FORTIS | 62,782 | 59.9 | 13.3% | — | 0.29 |
| MEDANTA | 38,551 | 69.3 | 21.9% | — | 0.10 |
| NH | 37,160 | 45.3 | 13.7% | — | 1.07 |
| LALPATHLAB | 32,549 | 46.8 | 29.6% | — | 0.00 |
| KIMS | 32,181 | 150.2 | 9.7% | — | 1.44 |
| POLYMED | 16,587 | 52.6 | 15.1% | — | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Execution risk in new hospital breakeven timelines — management targets 12–24 month payback, but occupancy volatility in emerging markets like Agartala and Raipur could delay profitability. 2. Margin pressure from aggressive capacity expansion — while current margins are improving, scaling new facilities may initially dilute profitability. 3. Regulatory and operational risks in Tier 2/3 markets — expansion into newer regions introduces compliance, talent acquisition, and market penetration challenges not present in mature Eastern India centers.
📋 Recent Filings
- Announcement2026-09-28GPT Healthcare announced that its trading window will close on October 1, 2026, for 48 hours after the release of un-audited Q2 results ending Septemb…
- 🔴 Announcement2026-09-21GPT Healthcare announced an analyst/investor meeting scheduled for September 28, 2026, to discuss its Q1FY27 presentation, which is publicly available…
- Announcement2026-08-04GPT Healthcare held an investor conference call on August 4, 2026, to discuss un-audited Q1 results ending June 30, 2026, confirming no unpublished pr…
- 🟡 Board Meeting2026-08-03GPT Healthcare Limited announced the outcome of its board meeting held on August 3, 2026, where it approved unaudited financial results for the quarte…
- Announcement2026-07-25GPT Healthcare announced an earnings call on August 4, 2026 at 11:00 AM IST to discuss un-audited Q1 FY27 results, inviting analysts and investors to …
- Announcement2026-07-11GPT Healthcare Limited announced receipt of a SEBI-approved certificate under Regulation 74(5) confirming no dematerialization/rematerialization reque…
- 🟡 Board Meeting2026-07-09GPT Healthcare Limited announced its 37th AGM scheduled for August 6, 2026, via video conferencing, with final dividend of **₹1.50 per share (15%)** p…
- 🟡 concall transcript2026-06-30GPT Healthcare reported 18.2% revenue growth and 66% PAT growth YoY in Q1 FY27, driven by strong occupancy and specialty mix, with EBITDA margin at 20…
- Financial Results2026-06-27GPT Healthcare Limited announced that its trading window will close on July 1, 2026, and remain closed for 48 hours after the release of un-audited Q1…
- Announcement2026-06-08GPT Healthcare Limited announced on June 8, 2026 that it has dispatched communications to shareholders with unpaid or unclaimed dividends as part of t…
🧠 Analyst's Read
GPT Healthcare is executing a clear expansion strategy with improving operational metrics, but investor focus will remain on the pace and profitability of new hospital ramp-ups. The next key milestone is Jamshedpur hospital commissioning by Q4 FY27, which will test scalability and execution discipline. Watch for updates on M&A progress and occupancy trends in high-growth but lower-margin segments.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when GPTHEALTH files new disclosures
Track GPTHEALTH filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GPTHEALTH — FreeFree account · 2 AI queries/day